Arun S. Singh, MD

Articles

Dr. Singh on Treatment for Patients With Uterine Leiomyosarcoma

September 21st 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses treatment for patients with uterine leiomyosarcoma.

Dr. Singh on the Use of Chemotherapy in Patients With Uterine Leiomyosarcomas

June 18th 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the use of chemotherapy in patients with uterine leiomyosarcomas.

Dr. Singh on Challenges in Leiomyosarcoma Treatment

June 12th 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the challenges of treating patients with leiomyosarcoma.

Dr. Singh on Drug Development for Patients With Soft Tissue Sarcomas

May 31st 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses drug development for the treatment of patients with soft tissue sarcomas.

Dr. Singh Discusses the Next Steps for Immunotherapy in GISTs

April 10th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the next steps following a trial investigating single-agent and combination immunotherapy for patients with gastrointestinal stromal tumors (GIST).

Dr. Singh Discusses Challenges for GIST

February 28th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses challenges for patients with gastrointestinal stromal tumors (GIST).

Dr. Singh Discusses the Future of Immunotherapy in GIST

February 1st 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the future of immunotherapy in gastrointestinal stromal tumors (GIST).

Dr. Singh Discusses Immunotherapy Study in GIST

January 26th 2018

Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

Dr. Singh Discusses Study of Nivolumab in Patients With GIST

January 19th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses a phase II study of nivolumab (Opdivo) in patients with metastatic unresectable gastrointestinal stromal tumors (GIST) during the 2018 Gastrointestinal Cancers Symposium.